If you've ever thought about investing in the gene-editing biotech space, Editas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) are doubtlessly familiar to you. While neither company ...

Quick Answer: Who Each Tool Is Best For Wondershare Filmora is best for creators, marketers, educators, and small teams ...

Within bacterial cells, specialized immune systems known as retrons fend off viral attacks. But that's not all they can do. Scientists, including Seth Shipman, Ph.D., at Gladstone Institutes, have ...

Editas Medicine (NASDAQ: EDIT) and Bluebird Bio (NASDAQ: BLUE) are both beaten-down gene-editing stocks. Editas' shares are down by 65% in the last 12 months, whereas Bluebird's have fallen by 40%.

Both Google’s Magic Editor and Samsung’s Generative Edit, which is part of its larger suite of Galaxy AI features, can be accessed the same way. You open a photo in Google Photos on your Pixel 8 or in ...

The Lead is a weekly newsletter that provides resources and connections for student journalists in both college and high school. Sign up here to have it delivered to your inbox every Wednesday morning ...

Editas Medicine and CRISPR Therapeutics are racing towards the same market. It looks like Bluebird Bio is going to be the player to beat in that market. Having enough cash on hand is a major factor ...

If you watched Samsung’s Galaxy S24 launch event or any of its ad spots, you’d be forgiven to think that Samsung is basically copying Google’s Magic Editor for its Generative Edit feature. As a matter ...